Pacific Biosciences Of Stock Investor Sentiment

PACB Stock  USD 1.56  0.05  3.11%   
About 61% of Pacific Biosciences' investor base is looking to short. The analysis of overall sentiment of trading Pacific Biosciences of stock suggests that many investors are alarmed at this time. The current market sentiment, together with Pacific Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Pacific Biosciences stock news signals to limit their universe of possible portfolio assets.
  
2 days ago at news.google.com         
Revolutionary DNA Tech Cracks Medical Mystery That Stumped Traditional Testing - StockTitan
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by Ordonez Kathy of 32179 shares of Pacific Biosciences at 1.65 subject to Rule 16b-3
Macroaxis News
over a week ago at zacks.com         
These 2 Medical Stocks Could Beat Earnings Why They Should Be on Your Radar
zacks News
over two weeks ago at simplywall.st         
Dont Ignore The Insider Selling In Pacific Biosciences of California
Simply Wall St News at Macroaxis
over two weeks ago at simplywall.st         
Selling Pacific Biosciences of California Shares at a Lower Price Than Current Market Value May Have...
Simply Wall St News at Macroaxis
over two weeks ago at zacks.com         
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped
zacks News
over two weeks ago at finance.yahoo.com         
PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Adv...
Yahoo News
over two weeks ago at gurufocus.com         
PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to ...
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue
Gurufocus Stories at Macroaxis
over two weeks ago at globenewswire.com         
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi ...
Macroaxis News: globenewswire.com
over two weeks ago at gurufocus.com         
Disposition of 34405 shares by Van Oene Mark of Pacific Biosciences at 2.034 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by ...
Gurufocus Stories at Macroaxis
over two weeks ago at thelincolnianonline.com         
Pacific Biosciences of California Stock Rating Upgraded by StockNews.com
news
over two weeks ago at finance.yahoo.com         
DNA Sequencing Research, Applied and Clinical Markets Report 2025 Innovation in Long-Read Sequencing...
Yahoo News
over three weeks ago at gurufocus.com         
PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay ...
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Pacific Biosciences that are available to investors today. That information is available publicly through Pacific media outlets and privately through word of mouth or via Pacific internal channels. However, regardless of the origin, that massive amount of Pacific data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pacific Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pacific Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pacific Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pacific Biosciences alpha.

Pacific Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Pacific Stock analysis

When running Pacific Biosciences' price analysis, check to measure Pacific Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacific Biosciences is operating at the current time. Most of Pacific Biosciences' value examination focuses on studying past and present price action to predict the probability of Pacific Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacific Biosciences' price. Additionally, you may evaluate how the addition of Pacific Biosciences to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
CEOs Directory
Screen CEOs from public companies around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios